Vigonvita Life Sciences Co., Ltd. (Ticker: 2630 HK) is a China-based biopharmaceutical company focusing on the discovery, acquisition, development, and commercialization of small-molecule drugs targeting neuropsychiatric and reproductive health disorders. Founded in 2013, Vigonvita has two core products under development: LV232, a dual-target serotonin transporter/5-HT3 receptor modulator for major depressive disorder, and TPN171, a type-5 phosphodiesterase (PDE5) inhibitor for erectile dysfunction. The company also has four drug candidates in clinical stages and three in pre-clinical development.

Vigonvita plans to list on the Hong Kong Stock Exchange (HKEX) on November 6, 2025, offering 17.6 million primary shares at an expected price range of HKD 32.00–34.00, aiming to raise approximately HKD 598.33 million (about $77 million). The IPO is managed by ABCI Capital, CCB International, CLSA, China Everbright Securities (HK), China Galaxy International Securities, and China International Capital Corporation (CICC).